Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiphospholipid syndrome and recurrent miscarriages.

D Vinatier1, P Dufour, M Cosson

  • 1Hôpital Jeanne de Flandre, Clinique de Gynécologie Obstétrique et Néonatalogie, Centre Hospitalier Universitaire de Lille, F59037 Cedex, Lille, France. dvinatier@chru-lille.fr

European Journal of Obstetrics, Gynecology, and Reproductive Biology
|April 20, 2001
PubMed
Summary

Antiphospholipid syndrome (APS) is a significant risk factor for recurrent pregnancy loss. While 7-25% of recurrent spontaneous abortions may be linked to APS, precise causation remains challenging due to diagnostic variability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mid-term outcomes after colpocleisis versus sacrospinous ligament fixation: VIGI-MESH registry.

European journal of obstetrics, gynecology, and reproductive biology·2025
Same author

Influence of experimental conditions on some in-vitro biomechanical properties of the sow's perineum.

Scientific reports·2024
Same author

Comparison of first versus second line sacrocolpopexies in terms of morbidity and mid-term efficacy.

Scientific reports·2022
Same author

Serious complications and recurrences after pelvic organ prolapse surgery for 2309 women in the VIGI-MESH registry.

BJOG : an international journal of obstetrics and gynaecology·2021
Same author

Long-term outcomes of primary cystocele repair by transvaginal mesh surgery versus laparoscopic mesh sacropexy: extended follow up of the PROSPERE multicentre randomised trial.

BJOG : an international journal of obstetrics and gynaecology·2021
Same author

[Trends in the use of midurethral slings after the new legislation: A nationwide survey].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2021

Area of Science:

  • Reproductive Immunology
  • Thrombosis and Hemostasis

Background:

  • Recurrent spontaneous abortion (RSA) affects a significant portion of pregnancies, with many cases remaining unexplained.
  • Antiphospholipid syndrome (APS) is a multisystem autoimmune disorder characterized by thrombosis and pregnancy complications, including recurrent pregnancy loss.
  • APS is implicated in 7-25% of RSA cases, highlighting its role as a major risk factor.

Purpose of the Study:

  • To review the association between Antiphospholipid syndrome (APS) and recurrent spontaneous abortion (RSA).
  • To discuss the challenges in accurately estimating the proportion of abortions caused by APS.
  • To explore potential mechanisms and current treatment strategies for APS in pregnancy.

Main Methods:

  • Literature review of epidemiological studies and recent research on APS and RSA.

Related Experiment Videos

  • Analysis of diagnostic criteria and standardization issues for antiphospholipid antibodies (aPLs).
  • Discussion of proposed treatment modalities including aspirin, corticosteroids, heparin, and IVIg.

    • Main Results:

    • APS is a recognized risk factor for RSA, but its exact contribution is difficult to quantify due to variable definitions and non-standardized assays.
    • Lupus anticoagulant (LA) and anticardiolipin antibodies (aCL) are the most standardized assays for routine use.
    • Emerging evidence suggests APS may also contribute to infertility and involves direct mechanisms on trophoblastic cells.

    Conclusions:

    • APS is a key consideration in the workup of recurrent spontaneous abortion.
    • Standardization of antiphospholipid antibody testing is crucial for accurate diagnosis and management.
    • Current treatment options aim to mitigate the thrombotic and pregnancy-related risks associated with APS.